• Customer Care
  • (888) 123-4567

Promoting Human Health
and Well Being

Read more

Our Science
Innovation

Merging our understanding of immune therapy with cutting-edge discoveries of how the microbiome functions, Rise is developing targeted immunotherapy drugs to treat a broad range of clinical indications.
Immunology

Immunology

We design immunological-based drugs to treat chronic diseases including autoimmunity, cancer, and infection.

Read more
Microbiome

Microbiome

Our understanding of microbiome science drives novel target identification and innovative drug design.

Read more
Synthetic Biology

Synthetic Biology

We use our proprietary oral biologics delivery technology to engineer novel immunological-directed cellular products.

Read more

Our Capabilities

PLATFORM

Synthetic Biology Medicine

As a foundational technology, Rise Therapeutics has developed the innovative and proprietary Tripartite X (TPX) drug delivery platform that embraces synthetic biology-based approaches to enable oral delivery of targeted biologic therapy.

Read more

INFRASTRUCTURE

Clinical
GMP
Manufacturing

Our clinical GMP drug production capabilities for microbial-based products including Live Biotherapeutic Products (LBPs) enables rapid and efficient translation of innovative bench discoveries towards commercialization.

Read more

Our Pipeline

At Rise Therapeutics, our product development focus, in-house clinical GMP manufacturing capabilities, and drug development experience enables us to pursue rapid and efficient novel drug development from innovative laboratory discoveries.
Image

Our Team

Gary Fanger, PHDFounder, President & CEO
Gary Fanger, PHD
Sathya Janardhanan, MS VP of Manufacturing
Sathya Janardhanan, MS

Interested in working with Us?

Become a Partner

Rise Therapeutics is interested in evolving key partnerships with leading academic, biotechnology, and pharmaceutical groups that share our interest and commitment to develop innovative new medicines.

Read more

Join Our Team

We are always looking for extraordinary people with exceptional creativity and enthusiasm. In our collaborative, high performing, and entrepreneurial environment, we work as a team to investigate life saving products and treatments.

Read more

Our News

Rockville, Maryland, January 31st, 2023 – Rise Therapeutics, a biopharmaceutical company engaged in developing novel oral synthetic biology medicines, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a Phase 1 clinical trial of its lead program candidate, R-3750.

Rockville, MD. Rise Therapeutics announced today that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has awarded a two-year Small Business Innovation Research (SBIR) Phase II award to fund the company’s further proof-of-concept testing of R-2487. R-2487 is Rise’s lead therapeutic candidate that represents a novel breakthrough approach for the treatment of Type 1 Diabetes (T1D). The promising features of this novel cellular synthetic biology medicine are focused on combining the safety of a probiotic with the functionality and specificity of target biological immunotherapy. 

Rockville, MD. Rise Therapeutics announced today that it has received funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institute of Health’s (NIH) to support proof-of-concept clinical testing of their lead therapeutic candidate, R-3750. R-3750 is a synthetic biology-based immune cellular medicine being developed for the treatment of Inflammatory Bowel Disease (IBD).